Lung Carcinoma (NSCLC) Profile Test

The Lung Carcinoma Profile measures multiple attributes related to lung carcinoma, including the following: • Genetic mutations such as EGFR gene alterations in Exon 19 deletion and Exon 21-L858R • Protein expression of ALK that helps identify anaplastic lymphoma kinase rearrangements • Histopathological features that provide information about the type and characteristics of the lung carcinoma

• To make an accurate diagnosis and subtyping of lung carcinoma • To identify specific genetic mutations and protein expressions that can guide targeted therapy decisions • To assess the prognosis and predict treatment response for non-small cell lung cancer (NSCLC) patients

The Lung Carcinoma Profile is recommended when: • there is a suspicion or diagnosis of lung carcinoma, especially non-small cell lung cancer, • determining the genetic mutations and protein expressions that may influence treatment options, or • evaluating treatment effectiveness or monitoring disease progression in NSCLC patients.

Abnormal results from the Lung Carcinoma Profile may indicate • specific genetic mutations or protein expressions associated with non-small cell lung cancer, • potential eligibility for targeted therapy or immunotherapy options, or • the need for further diagnostic tests or additional treatment considerations.

A tissue sample (FFPE block) obtained from a lung biopsy will be analysed. The sample will undergo PCR, FISH, Sanger sequencing, and IHC methods.

• Provide relevant clinical diagnosis, histopathology report, and any previous imaging or genetic testing reports related to lung carcinoma for accurate interpretation of results. • Inform your doctor if you have any specific requirements.

• Molecular testing for other genetic alterations like KRAS, BRAF, or ROS1 mutations • Blood tests for specific tumour markers like CEA (Carcinoembryonic Antigen) and CA 19-9

ALK by IHC for NSCLC

Non-small cell lung cancer is a type of lung cancer that accounts for around 85% of all lung cancer cases. It includes different subtypes, such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Each subtype has distinct characteristics and treatment approaches.